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Abstract
Background: Obesity and high blood pressure (HBP) pose high cardiovascular risks, and they are frequent causes of cardiovascular
disease.
Objective: The aim of this study was to validate the mobile app QardioArm for high blood pressure monitoring in obese subjects
(body mass index ≥30 kg/m2) according to guidelines in the European Society of Hypertension-International Protocol 2 (ESH-IP2).
Methods: We recruited 33 obese subjects and measured their blood pressure using QardioArm (test device) and Omron M3
Intellisense (Omron Healthcare, Kyoto, Japan; standard device). We compared systolic blood pressure (SBP), diastolic blood
pressure (DBP), and heart rate (HR) according to the ESH-IP2.
Results: A total of 95 of 99 differences for SBP and 91 of 99 for DBP displayed absolute differences within 10 mm Hg. A total
of 98 of 99 differences for SBP and 98 of 99 for DBP exhibited absolute differences within 15 mm Hg. This result satisfied
requirements for part 1 of the ESH-IP2. A total of 27 out of 33 individuals for SBP and 30 out of 33 individuals for DBP had a
minimum of 2 of 3 comparisons within 5 mm Hg difference. None of the subjects had 3 differences outside 5 mm Hg for SBP
and DBP, satisfying part 2 of the ESH-IP2. For HR measurements, a total of 90 of 99 differences had absolute differences within
3 beats per minute (bpm), and a total of 94 or 99 differences had absolute differences within 5 bpm. A total of 98 of 99 differences
had absolute differences within 8 bpm. Therefore, the test device satisfied part 1 of ESH-IP2 criteria for HR. For part 2 of ESH-IP2,
31 of 33 individuals had a minimum of 2 of 3 comparisons within 3 bpm difference for HR. Only 1 of 33 subjects had 3 differences
outside 3 bpm.
Conclusions: To the best of our knowledge, this was the first study to show that an app that measures blood pressure and HR
meets the requirements of the ESH-IP2 in an obese population. We believe the ESH-IP2 should publish explicit criteria for
validation of blood pressure devices in specific populations.
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Introduction
Obesity and high blood pressure (HBP) pose high cardiovascular
risks, and they are frequent causes of cardiovascular disease
[1]. They often influence the primary causes of morbidity and
mortality worldwide [2-5]. In adults, obesity is defined as body
mass index (BMI) greater than 30 kg/m2, with overweight
defined as BMI of 25 to 30 kg/m2, normal weight as BMI of
18.5 to 25 kg/m2, and underweight as BMI under 18.5
kg/m2[6,7]. HBP is defined as blood pressure (BP) of 140/90
mm Hg or more in adults 18 years of age or older who are not
taking medication for hypertension [8-15].
The prevalence of this disease in the world is around 20% to
30%, which may increase adverse cardiovascular events in the
obese population. These events are recognized by the physicians
and health policy makers as significant health problems because
of the several secondary impacts on the morbidity, mortality,
medical, and economic cost [16,17].
Obesity and HBP are closely related, as increases in weight and
BMI favor increases in BP. Conversely, weight loss reduces
obesity and hypertension [9,12,18]. Causal mechanisms for
obesity-associated hypertension include increased sympathetic
nervous system activity, increased renal sodium retention
secondary to insulin resistance or hyperinsulinemia, and
obesity-mediated inflammation [19-24]. Therefore, strict BP
control is necessary in obese individuals, as is weight reduction
with changes in diet, lifestyle, and physical activity [24,25].
Active involvement of patients in their own treatment is a crucial
factor in the successful management of hypertension. Home
blood pressure monitoring (HBPM) increases patient compliance
and has a great potential to improve hypertension control rates
[8-12,15,24-28].
Currently, HBPM is performed with new technologies, including
mobile apps, to obtain even greater benefits than can be obtained
with conventional devices [29-31]. In all cases,
self-measurement of BP at home requires a precise BP
measurement technique and an accurate sphygmomanometer
[25]. However, the primary disadvantage of automated home
sphygmomanometers is their inaccuracy [32]. The majority of
commercially available devices have not been evaluated
independently for accuracy [13,29-31,33-37]. To evaluate the
accuracy of devices in clinical practice, the Association for the
Advancement of Medical Instrumentation published a validation
protocol for electronic and aneroid sphygmomanometers in
1987. This was followed in 1990 by the protocol of the British
Hypertension Society; both protocols were revised in 1993
[38,39]. On the basis of these experiences, the Working Group
on Blood Pressure Monitoring of the European Society of
Hypertension (ESH) published a simplified protocol
(international protocol) to facilitate the evaluation process in
2002 that revised, unified, and simplified the previous guidelines
[40]. This most recent protocol of the ESH, revised in 2010
(ESH-IP2) was more demanding than the previous protocol
[32]. These protocols were meant for the general adult
population, and it should not be assumed that a device that has
been validated in the general population will be accurate in
specific populations such as obese patients [41].
A few studies [42-44] demonstrated the accuracy of automatic
BP monitors in specific populations such as obese patients, and
none validated a mobile app that measures BP following the
ESH protocol in this population. In 2017, QardioArm was
validated in the general [45,46] and diabetic populations [46].
We hypothesized that the QardioArm mobile app for HBPM
will show validated measures of BP and HR and will meet the
requirements of ESH-IP2 in an obese population. Moreover,
the purpose of this study was to validate the mobile app
QardioArm for HBPM, according to the ESH-IP2 in obese
subjects (BMI≥30 kg/m2) [6,7].
Methods
Ethics Approval
The Clinical Research Ethics Committee of Hospital Clínico
San Carlos in Madrid, Spain, approved this study (number
18/135-O_P_Tesis).
This study complied with the ethical principles of the
Declaration of Helsinki [47], including amendments from 2000
to 2013. Participants were informed regarding the study. All
participants gave written informed consent to participate.
The Devices
Omron M3 Intellisense
The Omron M3 Intellisense (Omron Healthcare, Kyoto, Japan)
was the standard device used as the benchmark. The device was
recently validated for the general population according to the
international protocol [48]. The Omron M3 Intellisense is an
automated oscillometric upper arm device for HBPM. The
standard cuff of the device is for arms with circumferences of
22 to 32 cm, and a large cuff is also available for arm
circumferences of 32 to 42 cm.
QardioArm
The QardioArm app (Qardioarm, Atten Electronic Co,
Dongguan, China) was the test device. QardioArm is a fully
automatic, noninvasive, and wireless BP monitor. This BP
measurement system is intended to measure SBP and DBP as
well as pulse rates in adults [49]. The unit uses an inflatable
cuff that wraps around the upper arm. The cuff circumference
is limited from 22 cm to 37 cm. To operate the device, a specific
free Qardio app can be downloaded from the Apple App Store
or Google Play (or getqardio website). It requires a device with
Bluetooth 4.0, iOS 7.0 (or later), Android 4.4 KitKat (or later),
and is compatible with iPhone, iPod, iPad, and Apple Watch,
as well as with Android phones and tablets.
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The QardioArm has an automatic screen with graphics and
visuals to facilitate interpretation of data. The app can be
configured to issue reminders and warnings, and the
measurements and progress can be shared in real time with other
users.
Patients and Recruitment
A consecutive sampling method was used to recruit the study
subjects in Ciudad Real (Spain) from family, as well as friendly
and known environments to the investigator.
According to the ESH-IP2 [32], a total of 33 participants who
satisfied inclusion and exclusion criteria were included. The
inclusion criteria were men and women aged at least 25 years.
Of the total participants, at least 10 must be men and 10 must
be women, with a BMI≥30 kg/m2. Exclusion criteria were
sustained arrhythmias, circulatory problems for which use of
the cuff was contraindicated, or pregnancy.
Study Protocol
The validation team consisted of 2 nurses with adequate
experience (more than 6 years) in BP measurement. The
measurement room was properly conditioned with an adequate
temperature and without any factor that could influence the
measurements, including noise and distractions [32,40]. Each
participant reported his or her gender and date of birth, and
weight, height, and BMI (calculated by the Quetelet´s equation
as BMI=weight in kilograms/height in meters squared) were
registered, and circumference of the arm was measured to ensure
that the cuff size was adequate. Subsequently, the subject relaxed
for 10 min and 9 consecutive BP measurements were performed
on the same arm, with the left arm at heart level, according to
the ESH-IP2 protocol [32,40]. Measurements were taken
alternating the Omron M3 Intellisense and the QardioArm app,
as follows:
• BPA: entry BP, with the standard device
• BPB: device detection BP with the test instrument
• BP1: with standard device
• BP2: with the test instrument
• BP3: with standard device
• BP4: with the test instrument
• BP5: with the standard device
• BP6: with the test instrument
• BP7: with the standard device
During measurement, the individual remained calm, quiet,
sitting, and not moving, with the back straight, keeping the feet
on the floor in a parallel position, without crossing the legs.
They rested the arm on a flat surface, with the palm of the hand
upwards and the elbow slightly flexed so that their arm was at
the height of the heart. The interval between BP measurements
was 30 to 60 seconds [32]. All measurements were made in the
same room.
Data Analysis
Statistical analyses were performed using IBM SPSS Statistics,
version 19 (SPSS Inc, Chicago, Illinois) [50]. The results were
expressed as mean (SD). The accuracy of a device according
to the ESH-IP2 was based on comparisons between the test
device (QardioArm) and the reference device (Omron M3)
measurements. For each subject, the device measurements BP2,
BP4, and BP6 were first compared with BP1, BP3, and BP5,
respectively, and then to the measurements BP3, BP5, and BP7,
respectively. Comparisons more favorable to the device were
used. Differences were classified separately for both SBP and
DBP according to whether the values were within 5, 10, or 15
mm Hg [32] and for the HR, according to whether the values
were within 3, 5, or 8 bpm. Results were analyzed and expressed
according to the ESH-IP2 requirements to determine whether
the device passed or failed the validation protocol. Parts 1 and
2 of the validation process concerned the number of differences
in the requested ranges for individual measurements (99
measurements) and for individual subjects (33 subjects) [32].
Bland-Altman graphs were used to represent the relationship
between the difference between SBP (device to reference) and
mean SBP (device and reference), DBP difference (device to
reference) and mean DBP (device and reference), or HR




A total of 36 subjects were screened: 14 males and 19 females.
Age, weight, height, BMI, arm circumference, and their mean
recruitment BP are displayed in Table 1.
Blood Pressure Measurements
The validation results for the QardioArm BP device according
to the ESH-IP2 are shown in Tables 2 and 3. The numbers of
measurements differing from the standard device Omron M3
by 5, 10, and 15 mm Hg or less are displayed in Tables 2 and
3, for SBP and DBP according to the ESH-IP2 [32]. The mean
differences between the standard and the tested device were
3.94 (SD 3.65) mm Hg for SBP and 3.25 (SD 3.80) mm Hg for
DBP. From these analyses, a total of 71 of 99 differences for
SBP presented an absolute difference within 5 mm Hg and 84
of 99 for DBP (vs at least 73 for SBP and 65 for DBP following
ESH-IP2 requirements).
A total of 95 of 99 comparisons for SBP displayed an absolute
difference within 10 mm Hg and 91 of 99 for DBP (vs at least
87 for SBP and 81 for DBP following ESH-IP2 requirements).
A total of 98 of 99 differences for SBP exhibited an absolute
difference within 15 mm Hg and 98 of 99 for DBP (vs at least
96 for SBP and 93 for DBP following ESH-IP2 requirements).
These data suggest that part 1 device validation was successfully
completed.
For part 2 of ESH-IP, 27 of 33 individuals had a minimum of
2 of 3 comparisons within 5 mm Hg difference for SBP and 30
of 33 subjects for DBP (vs at least 24 of 33 subjects for SBP
and DBP following ESH-IP2 requirements). None of the subjects
had 3 differences outside 5 mm Hg for SBP and DBP (vs a
maximum of 3 subjects for SBP and DBP following ESH-IP2
requirements). Because these 2 conditions were validated, part
2 device validation was successfully completed. Thus, part 3
of the QardioArm device validation passed, as parts 1 and 2
were both validated for SBP and DBP.
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Table 1. Sociodemographic characteristics of the participants.
Female (n=19)Male (n=14)Total group (n=33)Variables
RangeMean (SD)RangeMean (SD)RangeMean (SD)
28.0-83.060.84 (14.76)30.0-80.058.57 (15.70)28-8359.88 (14.97)Age in years
73.1-105.287.90 (9.47)80.02-125.195.35 (13.43)73.1-125.191.06 (11.74)Weight (kg)
156.0-182.0164.95 (6.28)160.0-183.0171.00 (6.74)156.0-183.0167.52 (7.06)Height (cm)
30.0-37.632.24 (2.23)30.0-37.432.46 (2.54)30.0-37.632.34 (2.33)Body mass index (kg/m2)
280.0-369.0329.37 (35.91)275-370308.93 (32.12)275.0-370.0320.70 (35.35)Arm circumference (mm)
112.0-176.0137.53 (16.08)117.0-175.0144.86 (16.42)112.0-176.0140.64 (16.38)Baseline systolic blood pressure
55.0-90.076.11 (7.41)60.0-98.078.50 (9.93)55.0-98.077.12 (8.51)Baseline diastolic blood pressure
Table 2. Validation results for the QardioArm blood pressure device part 1 according to European Society of Hypertension–International Protocol 2.
CriteriaValidation results QardioArm (Part 1a)






3.94 (3.65)Pass989571Systolic blood pressure
3.25 (3.80)Pass989184Diastolic blood pressure
aAccuracy is determined by the number differences in these ranges both for individual measurements (part 1) and for individual subjects (part 2). To
pass, a device must achieve all the minimum pass requirements shown.
bPass requirements: as required by the international protocol.
cNot applicable.
dAchieved: as recorded by the device.
Table 3. Validation results for the QardioArm blood pressure device parts 2 and 3 according to European Society of Hypertension–International Protocol
2.
CriteriaValidation results QardioArm (Part 2a)







aAccuracy is determined by the number differences in these ranges both for individual measurements (part 1) and for individual subjects (part 2). To
pass, a device must achieve all the minimum pass requirements shown.
bPass requirements: as required by the international protocol.
cAchieved: as recorded by the device.
dNot applicable.
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Table 4. Validation results for the QardioArm heart rate device part 1 according to the European Society of Hypertension–International Protocol 2,
presented as beats per minute (bmp).
CriteriaValidation results QardioArm (Part 1a)







aAccuracy is determined by the number differences in these ranges both for individual measurements (part 1) and for individual subjects (part 2). To
pass, a device must achieve all the minimum pass requirements shown.
bPass requirements: as required by the international protocol.
cNot applicable.
dAchieved: as recorded by the device.
Heart Rate Measurements
The validation results for the QardioArm HR device according
to the ESH-IP2 are shown in Tables 4 and 5. The numbers of
HR measurements differing from the standard device Omron
M3 by 3, 5, and 8 bpm or less are displayed in Tables 4 and 5
for HR. The mean difference between the standard and the test
device was 1.45 (SD 2.04) bpm.
From these analyses, a total of 90 of 99 differences presented
absolute differences within 3 bpm, and a total of 94 of 99
comparisons displayed absolute differences within 5 bpm. A
total of 98 of 99 differences exhibited absolute differences
within 8 bpm. Therefore, part 1 device validation was
successfully completed for HR.
For part 2 of ESH-IP, 31 of 33 individuals had a minimum of
2 of 3 comparisons within 3 bpm difference for HR. Only 1
subject had 3 differences outside 3 bpm. Since these 2
above-mentioned conditions were validated, part 2 device
validation was successfully completed. Thus, part 3 of the
QardioArm device validation passed, as parts 1 and 2 were both
validated for HR.
In summary, the QardioArm device met validation criteria of
the ESH-IP2 for SBP, DBP, and HR for subjects with BMI
greater than 30 kg/m2. These results agreed with the
Bland-Altman graphs showing differences between the
measurements with the QardioArm device and the Omron M3
for SBP (Figure 1, part A), DBP (Figure 1, part B), and HR
(Figure 1, part C).
Table 5. Validation results for the QardioArm heart rate device parts 2 and 3 according to the European Society of Hypertension–International Protocol
2, presented as beats per minute (bmp).
CriteriaValidation results QardioArm (Part 2a)






aAccuracy is determined by the number differences in these ranges both for individual measurements (part 1) and for individual subjects (part 2). To
pass, a device must achieve all the minimum pass requirements shown.
bPass requirements: as required by the international protocol.
cNot applicable.
dAchieved: as recorded by the device.
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Figure 1. Plots of systolic blood pressure (SBP; part A), diastolic blood pressure (DBP; part B), and heart rate (HR, part C) differences between the
QardioArm and the Omron M3.
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To the best of our knowledge, this was the first study providing
information regarding the accuracy of the QardioArm app for
measuring BP and HR in an obese population. This device had
previously been validated in the general population by our team
[45] and by others [46].
According to the ESH-IP2, we found that the QardioArm device
successfully passed the validation requirements in obese
population [32]. However, our results cannot be extrapolated
to other specific populations, including diabetic patients, the
elderly subjects, and pregnant women, as we did not address
these conditions.
Although it was not the objective of this study, we observed
that in obese people it was necessary to study various design
aspects. Despite the efforts of the manufacturers to improve the
quality of BP measuring devices, both the cuff and wrist
characteristics of devices remain a point of weakness in this
population [44].
In fact, although every participant was his own control, with 1
measurement recorded with QardioArm versus the reference
measurement recorded by the Omron M3, BP measurement in
some of our obese subjects presented some difficulties related
to arms shaped more like cones than like cylinders. In some
arms, the diameter at the top was larger than the diameter in the
region of the brachial artery [51]. Recent findings demonstrated
that despite using the appropriate cuff size, SBP appeared to be
higher in subjects with bigger arms [52], suggesting that a larger
limb may require greater pressure simply because there is more
tissue to compress and not necessarily because there is fatty
tissue. Indeed, they also observed that those with larger and
more muscular arms were more likely to be misclassified as
prehypertensive or hypertensive than those with smaller arms,
whereas those with smaller arms may be misclassified as normal
despite having elevated BP. We previously recommended that
a further correction factor for arm size may be needed even
when using the correct cuff size [52].
The high prevalence of obesity together with the problems
introduced by large arm circumferences present risks for
hypertension diagnoses [1-5,51,52]. We suggest that more
validation studies should be conducted on PA devices in the
obese population, as such studies are rare [42-44].
We used the ESH protocol that was published in 2002 [40] and
revised in 2010 [32]. This protocol shows many advantages
over previous protocols [38,39]. Nevertheless, it presents some
limitations. First, the ESH-IP2 did not specify the number of
validation studies that are needed to validate the instrument
despite some findings reporting that a device should be validated
in no fewer than 2 different centers separately [41,45,46,48].
Therefore, it is important to check the validity of BP measuring
devices in specific populations as an add-on step to the
validation process before widespread application in clinics or
homes. Second, the specific conditions required for the recruited
subjects in the study exclude children and young people,
omitting data from the obese population aged between 18 and
25 years. Third, there was no mention of an explicit criterion
for a validation process in specific populations in the ESH-IP,
and we highly recommend that this would be taken into account
in the next revision. Fourth, despite the fact that sample size
calculation was conducted, the consecutive sampling bias should
be considered and a simple randomization sampling process
could be more adequate for future studies. Finally, despite the
sphygmomanometers measure for SBP, DBP, and HR, there is
no version of the International Protocol of the ESH to consider
validation of HR. Therefore, validation based on the protocol
criteria in BP should be added and established, in this case, the
required differences based on the scale of values found after
HR measurements being even more demanding than those of
the ESH.
Conclusions
To the best of our knowledge, this was the first study to show
that an app that measures BP and HR meets the requirements
of ESH-IP2 in an obese population. We believe the ESH-IP2
should publish explicit criteria for validation of BP devices in
specific populations. Finally, we highly recommend assessment
of the accuracy of this app in other specific populations such
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